Last reviewed · How we verify
Pregabalin Dose Level 2
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury), Partial-onset seizures (adjunctive therapy), Generalized anxiety disorder.
At a glance
| Generic name | Pregabalin Dose Level 2 |
|---|---|
| Also known as | Lyrica Dose Level 2 |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Gabapentinoid; anticonvulsant; anxiolytic; analgesic |
| Target | Alpha-2-delta subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology; Pain Management; Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By binding to presynaptic calcium channels, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, norepinephrine, and substance P. This modulation of neurotransmitter release underlies its analgesic, anxiolytic, and anticonvulsant effects. The drug is used across multiple neurological and pain conditions where excessive neuronal excitability contributes to pathology.
Approved indications
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury)
- Partial-onset seizures (adjunctive therapy)
- Generalized anxiety disorder
- Fibromyalgia
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema (peripheral)
- Weight gain
- Blurred vision
- Ataxia
Key clinical trials
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial (NA)
- The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia (NA)
- Efficacy and Safety of Pregabalin/Tizanidine vs. Pregabalin in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |